93. Primary biliary cholangitis Clinical trials / Disease details
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01614405 (ClinicalTrials.gov) | June 2012 | 25/4/2011 | Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis | Randomized Controlled Pilot Study of Highly Active Anti-Retroviral Therapy for Patients With Primary Biliary Cirrhosis | Primary Biliary Cirrhosis | Drug: Truvada and Kaletra | University of Alberta | Abbott;Gilead Sciences;Canadian Institutes of Health Research (CIHR) | Completed | 18 Years | N/A | Both | 13 | N/A | Canada |